Single drug treatment with the small molecule ALK/MET inhibitor crizotinib has shown very promising results in adult non-small cell lung cancer and in large cell anaplastic lymphoma that harbour ALK translocations16. This evidence concerns the gene ALK and anaplastic large cell lymphoma.